-- Earnings Flash (SESN) SESEN BIO Reports Q2 Loss $-0.16
8:01AM ET 8/08/2022 MT Newswires...
Sesen Bio (SESN) said Monday it has paused the clinical development of Vicineum, its therapeutic candidate for non-muscle invasive bladder cancer, in the...
Sesen Bio (SESN) said Friday that it is no longer seeking a reverse stock split of its common shares to avoid a potential delisting. The late-stage...
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral...
Address | 245 First Street Cambridge, Massachusetts 02142 |
Phone | +1.617.444.8550 |
Number of Employees | 24 |
Recent SEC Filing | 08/11/2022![]() |
President, Chief Executive Officer & Director | Thomas R. Cannell |
Chief Financial Officer & Treasurer | Monica Forbes |
Finance Director | Stephanie Vigue |
Head of Research | Jeannick Cizeau |
Price Open | $0.71 |
Previous Close | $0.70 |
52 Week Range | $0.37 - 6.04 |
Market Capitalization | $139.6 M |
Shares Outstanding | 199.5 M |
Sector | Health Technology |
Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/14/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | 2.92 |
Earnings per Share | -$0.13 |
Beta vs. S&P 500 | N/A |
Revenue | $0.00 |
Net Profit Margin | 238.99% |
Return on Equity | 29.51% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |